Abstract
An HPLC-UV method was developed for simultaneously quantifying 13 major components in Semen Oroxyli, a commonly used traditional Chinese medicinal herb, including scutellarin, quercetin-3-O-α-L-arabinopyranoside, oroxin B, chrysin-7-O-β-D-gentiobioside, baicalin, oroxin A, scutellarein, chrysin-7-O-β-D-glucuronide, quercetin, norwogonine, baicalein, chrysin and oroxylin A. The optimal conditions of separation and detection were achieved on an Agilent Zorbax SB-C18 column (250 mm x 4.6 mm, 5 μm) with a gradient elution of acetonitrile and 0.3% (v/v) acetic acid at a flow rate of 1.0 ml/min, with a detection wavelength of 277 nm. A complete separation was obtained within 50 min for the 13 target compounds. All calibration curves showed good linearity (r2 > 0.9997) within the testing range. The assay was reproducible with overall intra-and inter-day variation of less than 3%. The mean spiked recovery of all analytes was 100 ± 10%, with RSD less than 5%. The validated method was successfully applied to quantitatively analyse 13 flavonoids for quality evaluation of commercial Semen Oroxyli samples from different locations.
Keywords: Baicalin, Chrysin-7-O-β-D-glucuronide, Flavonoids, HPLC, Oroxin A, Oroxin B, Oroxylum indicum, Quantification, Scutellarein, Semen Oroxyli
Current Pharmaceutical Analysis
Title:Quality Evaluation of Semen Oroxyli through Simultaneous Quantification of 13 Components by High Performance Liquid Chromatography
Volume: 8 Issue: 2
Author(s): Yan-Qing Zhou, Qing-Wen Zhang, Song-Lin Li, Zhi-Qi Yin, Xiao-Qi Zhang and Wen-Cai Ye
Affiliation:
Keywords: Baicalin, Chrysin-7-O-β-D-glucuronide, Flavonoids, HPLC, Oroxin A, Oroxin B, Oroxylum indicum, Quantification, Scutellarein, Semen Oroxyli
Abstract: An HPLC-UV method was developed for simultaneously quantifying 13 major components in Semen Oroxyli, a commonly used traditional Chinese medicinal herb, including scutellarin, quercetin-3-O-α-L-arabinopyranoside, oroxin B, chrysin-7-O-β-D-gentiobioside, baicalin, oroxin A, scutellarein, chrysin-7-O-β-D-glucuronide, quercetin, norwogonine, baicalein, chrysin and oroxylin A. The optimal conditions of separation and detection were achieved on an Agilent Zorbax SB-C18 column (250 mm x 4.6 mm, 5 μm) with a gradient elution of acetonitrile and 0.3% (v/v) acetic acid at a flow rate of 1.0 ml/min, with a detection wavelength of 277 nm. A complete separation was obtained within 50 min for the 13 target compounds. All calibration curves showed good linearity (r2 > 0.9997) within the testing range. The assay was reproducible with overall intra-and inter-day variation of less than 3%. The mean spiked recovery of all analytes was 100 ± 10%, with RSD less than 5%. The validated method was successfully applied to quantitatively analyse 13 flavonoids for quality evaluation of commercial Semen Oroxyli samples from different locations.
Export Options
About this article
Cite this article as:
Zhou Yan-Qing, Zhang Qing-Wen, Li Song-Lin, Yin Zhi-Qi, Zhang Xiao-Qi and Ye Wen-Cai, Quality Evaluation of Semen Oroxyli through Simultaneous Quantification of 13 Components by High Performance Liquid Chromatography, Current Pharmaceutical Analysis 2012; 8 (2) . https://dx.doi.org/10.2174/1573412911208020206
DOI https://dx.doi.org/10.2174/1573412911208020206 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Anticancer Drugs in Reproductive Parameters of Juvenile Male Animals and Role of Protective Agents
Anti-Cancer Agents in Medicinal Chemistry Development on PEG-modified Poly (Amino Acid) Copolymeric Micelles for Delivery of Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Targeting Thioredoxin Reductase: Anticancer Agents and Chemopreventive Compounds
Medicinal Chemistry Ethnopharmacology, Phytochemistry and Biological Activities of Native Chilean Plants
Current Pharmaceutical Design The Role of the Calcium-Sensing Receptor in Bone Biology and Pathophysiology
Current Pharmaceutical Biotechnology New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents Drosophila Neoplasias: Clues Towards the Understanding of Human Cancers
Current Genomics Feud or Friend? The Role of the miR-17-92 Cluster in Tumorigenesis
Current Genomics Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer
Current Drug Delivery Emerging Therapeutic Agents for Cervical Cancer
Recent Patents on Anti-Cancer Drug Discovery Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design Challenging the Evidence Based Medicine Principles Among Clinical Obesity Treatments
Current Clinical Pharmacology Recent Advances in the Development of Catalytic Inhibitors of Human DNA Topoisomerase IIα As Novel Anticancer Agents
Current Medicinal Chemistry Endocannabinoids in Appetite Control and the Treatment of Obesity
CNS & Neurological Disorders - Drug Targets Current Approaches for in vitro Drug Release Study of Long Acting Parenteral Formulations
Current Drug Delivery Natural Compounds Promoting Weight Loss: Mechanistic Insights from the Point of View of the Medicinal Chemist
The Natural Products Journal The Role of Tumor-related LncRNA PART1 in Cancer
Current Pharmaceutical Design